Q32 Bio (NASDAQ:QTTB) Posts Earnings Results, Beats Estimates By $0.14 EPS

Q32 Bio (NASDAQ:QTTB) posted its earnings results on Tuesday. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.14, FiscalAI reports.

Q32 Bio Stock Performance

Shares of QTTB traded down $0.05 during mid-day trading on Thursday, hitting $5.42. The company’s stock had a trading volume of 154,779 shares, compared to its average volume of 258,122. The stock’s 50-day moving average is $5.88 and its two-hundred day moving average is $4.16. The firm has a market capitalization of $84.73 million, a PE ratio of 2.04 and a beta of -0.05. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.85 and a current ratio of 4.85. Q32 Bio has a one year low of $1.35 and a one year high of $8.05.

Analyst Ratings Changes

A number of research analysts recently issued reports on QTTB shares. Zacks Research upgraded shares of Q32 Bio from a “hold” rating to a “strong-buy” rating in a report on Thursday, March 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Q32 Bio in a report on Friday, January 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Q32 Bio in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Q32 Bio currently has a consensus rating of “Moderate Buy” and an average price target of $13.00.

Key Headlines Impacting Q32 Bio

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright raised multiple near‑term and multi‑year EPS forecasts and reiterated a Buy rating with a $13 price target; the firm’s analyst J. Pantginis trimmed projected losses for Q2, Q3 and Q4 2026 (to ($0.48), ($0.50) and ($0.52) respectively) and improved FY2026–FY2028 and out‑year forecasts (FY2026 to ($2.04) from ($2.21); FY2027 to ($2.00); FY2028 to ($1.80); FY2029 to $0.20; FY2030 to $0.44). The revisions signal improved analyst confidence in the company’s longer‑term model and are a clear positive for valuation expectations. MarketBeat: Q32 Bio coverage
• Negative Sentiment: Q32 disclosed internal control challenges under Sarbanes‑Oxley (accounting & financial operations risk). Such SOX‑related weaknesses can lead to audit issues, higher compliance costs, delayed filings or restatements — all of which can pressure sentiment and create short‑term selling even when analyst models are improved. Investors should watch company filings and remediation plans closely. Regulatory Compliance Risks (TipRanks)

Insider Transactions at Q32 Bio

In related news, CEO Jodie Pope Morrison sold 9,896 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total transaction of $44,630.96. Following the completion of the transaction, the chief executive officer directly owned 89,104 shares in the company, valued at $401,859.04. This represents a 10.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 16,706 shares of company stock worth $75,344 over the last 90 days. Insiders own 40.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Marshall Wace LLP bought a new stake in shares of Q32 Bio in the second quarter valued at about $25,000. ADAR1 Capital Management LLC bought a new position in Q32 Bio during the fourth quarter valued at about $66,000. XTX Topco Ltd bought a new position in Q32 Bio during the fourth quarter valued at about $68,000. HRT Financial LP raised its holdings in Q32 Bio by 66.5% in the 4th quarter. HRT Financial LP now owns 24,698 shares of the company’s stock valued at $81,000 after acquiring an additional 9,862 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Q32 Bio in the 4th quarter worth approximately $84,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.